|
|
||||||||
Experimental Studies |
1 From the Department of Radiology, Contrast Media Laboratory, University of California, San Francisco, Box 0628, 513 Parnassus Ave, San Francisco, CA 94143-0628. Received October 6, 1998; revision requested December 14; revision received December 28; accepted April 8, 1999. Address reprint requests to R.C.B.
PURPOSE: To differentiate prostate cancers of different histopathologic grades with dynamic gadolinium-enhanced magnetic resonance (MR) imaging. Results with a conventional small-molecular contrast medium (CM) were compared to those with a prototypic macromolecular CM.
MATERIALS AND METHODS: High- and low-grade tumors, sublines of the Dunning R3327 rat prostate cancer line, were subcutaneously implanted into the flanks of 12 male Copenhagen rats. Dynamic contrast materialenhanced MR imaging was performed with small-molecular CM and macromolecular CM at an interval of 1 day. Microvascular permeability, as estimated with the endothelial transfer coefficient, and fractional plasma volume were calculated for each tumor and each CM by means of a two-compartmental, bidirectional kinetic model.
RESULTS: Mean endothelial transfer coefficient values for both macromolecular CM and small-molecular CM were significantly different between the two tumor sublines (P = .0004 and P = .01, respectively). For the high- and low-grade tumors, no overlap of values was seen with macromolecular CM, but a broad overlap was seen with small-molecular CM despite a significant difference in mean values.
CONCLUSION: Dynamic contrast-enhanced MR imaging permits differentiation of histopathologic prostatic tumor types. Quantitative microvascular permeability characteristics estimated from macromolecular CMenhanced data were significantly superior to those derived from small-molecular CMenhanced data.
Index terms: Gadolinium Magnetic resonance (MR), contrast media, 844.121412, 844.12143 Prostate, MR, 844.121412, 844.12143 Prostate, neoplasms,844.32
This article has been cited by other articles:
![]() |
H.-J. Raatschen, G. H. Simon, Y. Fu, B. Sennino, D. M. Shames, M. F. Wendland, D. M. McDonald, and R. C. Brasch Vascular Permeability during Antiangiogenesis Treatment: MR Imaging Assay Results as Biomarker for Subsequent Tumor Growth in Rats Radiology, May 1, 2008; 247(2): 391 - 399. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Jain, S.K. Ellika, L. Scarpace, L.R. Schultz, J.P. Rock, J. Gutierrez, S.C. Patel, J. Ewing, and T. Mikkelsen Quantitative Estimation of Permeability Surface-Area Product in Astroglial Brain Tumors Using Perfusion CT and Correlation with Histopathologic Grade AJNR Am. J. Neuroradiol., April 1, 2008; 29(4): 694 - 700. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. N. Bloch, E. Furman-Haran, T. H. Helbich, R. E. Lenkinski, H. Degani, C. Kratzik, M. Susani, A. Haitel, S. Jaromi, L. Ngo, et al. Prostate Cancer: Accurate Determination of Extracapsular Extension with High-Spatial-Resolution Dynamic Contrast-enhanced and T2-weighted MR Imaging Initial Results Radiology, October 1, 2007; 245(1): 176 - 185. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Marzola, A. Degrassi, L. Calderan, P. Farace, E. Nicolato, C. Crescimanno, M. Sandri, A. Giusti, E. Pesenti, A. Terron, et al. Early Antiangiogenic Activity of SU11248 Evaluated In vivo by Dynamic Contrast-Enhanced Magnetic Resonance Imaging in an Experimental Model of Colon Carcinoma Clin. Cancer Res., August 15, 2005; 11(16): 5827 - 5832. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. F. Jordan, M. Runquist, N. Raghunand, R. J. Gillies, W. R. Tate, G. Powis, and A. F. Baker The Thioredoxin-1 Inhibitor 1-Methylpropyl 2-Imidazolyl Disulfide (PX-12) Decreases Vascular Permeability in Tumor Xenografts Monitored by Dynamic Contrast Enhanced Magnetic Resonance Imaging Clin. Cancer Res., January 15, 2005; 11(2): 529 - 536. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Engelbrecht, H. J. Huisman, R. J. F. Laheij, G. J. Jager, G. J. L. H. van Leenders, C. A. Hulsbergen-Van De Kaa, J. J. M. C. H. de la Rosette, J. G. Blickman, and J. O. Barentsz Discrimination of Prostate Cancer from Normal Peripheral Zone and Central Gland Tissue by Using Dynamic Contrast-enhanced MR Imaging Radiology, October 1, 2003; 229(1): 248 - 254. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. S. Kuszyk, F. M. Corl, F. N. Franano, D. A. Bluemke, L. V. Hofmann, B. J. Fortman, and E. K. Fishman Tumor Transport Physiology: Implications for Imaging and Imaging-Guided Therapy Am. J. Roentgenol., October 1, 2001; 177(4): 747 - 753. [Full Text] [PDF] |
||||
![]() |
K. Turetschek, S. Huber, E. Floyd, T. Helbich, T. P. L. Roberts, D. M. Shames, K. S. Tarlo, M. F. Wendland, and R. C. Brasch MR Imaging Characterization of Microvessels in Experimental Breast Tumors by Using a Particulate Contrast Agent with Histopathologic Correlation Radiology, February 1, 2001; 218(2): 562 - 569. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| RADIOLOGY | RADIOGRAPHICS | RSNA JOURNALS ONLINE |